WhiteOak Capital Phrm and Hlthcr

All Cap

Equity

Health Care

India Super Value

Others

Emotionally driven

Investor Profile

1–7 yearsInvestment Horizon

HNI, UHNI, Retail Investor, Mass AffluentTarget Segments

SEBI registered equity mutual fund suitable for all investor categoriesRegulatory Fit

Whiteoak Capital Pharma And Healthcare Fund Growth focuses on Indian healthcare and pharma companies for steady growth.

What This Strategy Does

WhiteOak Capital Phrm and Hlthcr Reg Gr is an equity fund which captures India's ₹2.5 trillion healthcare opportunity through a concentrated portfolio, deploying capital across pharmaceuticals and healthcare services to achieve broad-based earnings growth.

CW Expert Research Notes

Consistent Outperformance

The fund has demonstrated resilient benchmark-relative behavior, outperforming in 2 out of the last 12 years, suggesting a robust investment process capable of delivering consistent earnings and downside protection.

Concentrated Healthcare Exposure

With a 93.37% allocation to the healthcare sector and a mid-cap tilt, the fund's differentiated construction expresses high conviction in pharmaceutical and healthcare stocks, offering a distinct exposure narrative versus peers.

Defensive Growth Opportunity

Positioned as a defensive growth strategy with a reasonable valuation, the fund could benefit from structural healthcare tailwinds, while its low beta of 1.004 and sharpe ratio of 1.159 suggest a favorable risk-reward profile.

Performance and Risk Analysis

Historical returns, volatility patterns, and how this fund has performed relative to its benchmark.

Fund Performance

5.0% AnnuallyAlpha

+0.0% vs +0.0% benchmarkSince Inception

+0.0% vs +0.0% benchmark3Y Annualized

+0.0% vs +0.0% benchmark5Y Annualized

WhiteOak Capital Phrm and Hlthcr

Benchmark Index

Benchmark Performance Comparison

Whiteoak Capital Pharma And Healthcare Fund

NIFTY 50

Given the product’s limited performance history, the assessment considers the fund house’s track record and the historical performance of comparable strategies managed by the same fund house, which follow similar investment approaches. Such comparisons provide historical context only and do not represent the performance of the new product or indicate its future returns.

Risk Profile

Standard Deviation15.0%

Maximum Drawdown-15.2% | Jan 2025

Sharpe Ratio1.16

Beta1.00

Upside Capture96%

Detailed Risks

Market Risk

Recession-driven healthcare spending cuts could pressure earnings for fund holdings.

Disclaimer: Products compared like fixed deposits may provide fixed guaranteed returns. Mutual Funds investments are subject to market risk, read all scheme related documents carefully before investing. Past performance is not an indicator of future returns.

Strategy Details

A closer look at the investment thesis, portfolio construction, and current holdings.

Core Investment Theme

Provides concentrated exposure to India's rapidly growing healthcare and pharmaceutical sectors. This theme capitalizes on the country's rising medical needs, favorable demographics, and increasing healthcare spending—driven by an expanding middle class and government initiatives to improve access.

Broader Market View

Market Outlook

The global economy faces headwinds from elevated inflation and tightening monetary policies. However, opportunities exist in sectors poised to benefit from secular trends like digitalization and sustainability.

Why This Strategy is Attractive Now

This strategy aims to capitalize on long-term structural growth drivers while mitigating risks through diversification. Its focus on quality companies with sustainable competitive advantages could provide resilience during market volatility.

Investment Style & Process

Investment Style

The portfolio exhibits characteristics of a Quality Growth strategy, emphasizing companies with durable competitive advantages, consistent earnings growth, and reasonable valuations.

Why it Makes Sense

In the current environment of moderating economic growth and elevated uncertainty, a Quality Growth approach offers exposure to resilient businesses with pricing power and sustainable growth trajectories.

High-Level Investment Process

Sourcing: The strategy appears to favor companies with strong franchises, healthy balance sheets, and attractive growth runways across both secular and cyclical sectors. Selection: The process suggests a preference for businesses with robust profitability, disciplined capital allocation, and reasonable valuations relative to growth prospects. Construction: Portfolio construction is consistent with a focus on managing risk through diversification across sectors and market capitalizations.

Portfolio Holdings Overview

SectoralAllocation

Services93.37%

Capital Goods6.63%

Geographic Allocation

Domestic100%

Top Stock Holdings

CompanySectorAllocation

Divi's Laboratories LtdServices8.45%

Sun Pharmaceuticals Industries LtdServices7.40%

Torrent Pharmaceuticals LtdServices6.78%

Apollo Hospitals Enterprise LtdServices4.73%

Laurus Labs LtdServices3.78%

Sai Life Sciences LtdServices3.32%

Cipla LtdServices3.25%

Max Healthcare Institute Ltd Ordinary SharesServices3.05%

Neuland Laboratories LtdServices2.88%

Ipca Laboratories LtdServices2.66%

Fund House Management

The asset management company’s track record, AUM scale, and fund manager credentials.

Fund Manager Track Record

Ashish Agrawal

Lead Portfolio Manager

Ashish Agrawal has experience of 2 years. Manages 56 funds at WhiteOak Capital Asset Management Limited with an AUM of approximately ₹11,159 Cr

Trupti Agrawal

Co-Portfolio Manager

Trupti Agrawal has experience of 4 years. Manages 56 funds at WhiteOak Capital Asset Management Limited with an AUM of approximately ₹11,159 Cr

Dheeresh Pathak

Co-Portfolio Manager

Mr. Dheeresh Pathak has experience of 20 years. Manages 56 funds at WhiteOak Capital Asset Management Limited with an AUM of approximately ₹11,159 Cr Holds a B.Com degree.

Piyush Baranwal

Co-Portfolio Manager

Mr. Piyush Baranwal has experience of 19 years. Manages 92 funds at WhiteOak Capital Asset Management Limited with an AUM of approximately ₹11,733 Cr Holds a PGDBM degree.

Ramesh Mantri

Co-Portfolio Manager

Mr. Ramesh Mantri has experience of 24 years. Manages 58 funds at WhiteOak Capital Asset Management Limited with an AUM of approximately ₹11,159 Cr Holds a M.B.A. degree.

Trupti Agrawal

Co-Portfolio Manager

Trupti Agrawal has experience of 4 years. Manages 56 funds at WhiteOak Capital Asset Management Limited with an AUM of approximately ₹11,159 Cr

Dheeresh Pathak

Co-Portfolio Manager

Mr. Dheeresh Pathak has experience of 20 years. Manages 56 funds at WhiteOak Capital Asset Management Limited with an AUM of approximately ₹11,159 Cr Holds a B.Com degree.

Piyush Baranwal

Co-Portfolio Manager

Mr. Piyush Baranwal has experience of 19 years. Manages 92 funds at WhiteOak Capital Asset Management Limited with an AUM of approximately ₹11,733 Cr Holds a PGDBM degree.

Ramesh Mantri

Co-Portfolio Manager

Mr. Ramesh Mantri has experience of 24 years. Manages 58 funds at WhiteOak Capital Asset Management Limited with an AUM of approximately ₹11,159 Cr Holds a M.B.A. degree.

CW Expert Take

WhiteOak Capital applies focused expertise in the healthcare and pharmaceuticals space. Their investment philosophy centers on identifying quality franchises with sustainable growth drivers. The fund house maintains disciplined frameworks for evaluating business models and competitive advantages, particularly valuable in a regulated sector like healthcare. WhiteOak combines bottom-up research with top-down thematic insights to construct high-conviction equity portfolios.

68 years

Combined Team Experience

₹ 56,369 Cr

Assets Under Management

Firm Overview

AMCWhiteOak Capital Asset Management Limited

Total AUM₹29,798.08 Cr

Investment Philosophy & Approach

Focused Expertise

WhiteOak Capital employs a focused investment approach in healthcare and pharmaceuticals.

Disciplined Process

The fund house follows a disciplined investment process and risk management framework.

Long-Term Mindset

WhiteOak Capital maintains a long-term capital allocation mindset for its investments.

Operational & Regulatory Details

What it costs to invest, transaction mechanics, and regulatory disclosures you should know.

Costs and Fees

Total Expense Ratio (TER)2.8%

Regulatory & Tax Information

INF03VN01878

ISIN

DailyDealing Frequency

BSE Healthcare PR INRBenchmark

LTCG | >1Year 12.5%% on gain above 1.25 Lakh

STCG | <1Year 20%%

Tax Implications (India)